🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04597164
Recruiting Observational

Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

NCT04597164 · tracked via the Priya Life Science China tracker
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Observational
Started
2020-12-22
Last updated
2024-11-29

Condition(s) studied

Hepatitis B, ChronicAcute-On-Chronic Liver Failure

Investigational drug(s) / intervention(s)

Artificial liver support system

Artificial liver support system: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.

Study summary

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year); 2. Age from 18 to 65 years old; 3. Clinical diagnosis of liver failure (serum total bilirubin level \> 10 times upper limit of normal; prothrombin time activity \< 40% and ≥20%, or prothrombin time international ratio ≤ 2.6 and \> 1.5); 4. Platelets \> 50\*10 E9/L. Exclusion Criteria: 1. Other active liver diseases; 2. Hepatocellular carcinoma or other malignancy; 3. Pregnancy or lactation; 4. Human immunodeficiency virus infection or congenital immune deficiency diseases; 5. Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events; 6. Other important organ dysfunctions or transplantation; 7. Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome; 8. Patients can not follow-up; 9. Investigator considering inappropriate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong Recruiting

More Third Affiliated Hospital, Sun Yat-Sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04597164 on ClinicalTrials.gov ↗ ← All trials in China